Market research
THEMISMED.NSE Themis Medicare Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 9B
- P/E ratio
- 22.11
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.55
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE083B01024
- Market cap
- 9B
- P/E ratio
- 22.11
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.55
About
About Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It provides active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, haematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasopressors, vitamins, and weight management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.
Research context
Themis Medicare Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the THEMISMED.NSE discussion.
5 years, 6 months ago
Themis Medicare Limited is currently in a long term uptrend where the price is trading 82.8% above its 200 day moving average.
From a valuation standpoint, the stock is 72.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Themis Medicare Limited's total revenue rose by 21.8% to $655M since the same quarter in the previous year.
Its net income has increased by 10.3% to $118M since the same quarter in the previous year.
Finally, its free cash flow grew by 487.1% to $313M since the same quarter in the previous year.
Based on the above factors, Themis Medicare Limited gets an overall score of 5/5.